Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New US legislation Aims to Phase Out Invasive Research on Great Apes

By LabMedica International staff writers
Posted on 14 Aug 2012
US Senate Environment and Public Works Committee recently approved the Great Ape Protection and Cost Savings Act (S. More...
810) and urged its passage in the full US Senate. Since Chimpanzees are the only great apes currently used in invasive research in the US, the new legislation will phase out such research on chimpanzees, end breeding of chimpanzees for invasive research purposes, and retire the 500 government-owned chimpanzees to sanctuary, saving approximately USD 25 million per year.

However, according to the act, the term Great Ape refers to Chimpanzees (Pan troglodytes), Bonobos (P. paniscus), Gorillas (Gorilla gorilla or G. beringei), Orangutans (Pongo pygmaeus or Pongo abelii), and Gibbons (Hylobatidae).

The bill was introduced by US Senators Maria Cantwell, Democrat-Washington, Susan Collins, Republican-Maine, and Bernard Sanders, Independent-Vermont.

S. 810 passed the committee by voice vote with the inclusion of an amendment that allows for invasive research on great apes in the event that a new, emerging, or reemerging disease requires their use. Approval for research will involve a transparent process that closely tracks the recommendations of a recent Institute of Medicine of the [US] National Academies (IOM; Washington DC, USA) report that concluded chimpanzees are largely unnecessary for current biomedical research.

The Great Ape Protection and Cost Savings Act was introduced in April 2011. A recent report by the Institute of Medicine and National Research Council could not identify any area of current biomedical research for which chimpanzee use is necessary. Moreover, the report pointed to several available alternatives to chimpanzee use and called for increased support for the development of more alternative research methods. Prior to the IOM report, approximately 80%-90% of chimpanzees in laboratories were not being used and instead are warehoused in laboratories at a high cost to US taxpayers. Sanctuaries can provide higher standards of care at a lower cost to taxpayers.

Related Links:

Institute of Medicine




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.